Placental Transfer of SSRI and SNRI Antidepressants and Effects on the Neonate

Abstract

Introduction: We investigated placental transfer and neurobehavioural effects in neonates exposed to citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine or sertraline (SSRI's), or to venlafaxine (an SNRI).

Methods: Women receiving antidepressants during pregnancy and their neonates were studied. Cord and maternal drug concentrations were measured at birth and in the neonates plasma on day 3. Neonates were also assessed using a range of neurobehavioral tests and compared to controls.

Results: Median cord/maternal distribution ratio was 0.7–0.86 (range) for SSRIs, 0.72 for the SNRI venlafaxine and 1.08 for the O-desmethyl metabolite. Neonatal abstinence scores were significantly higher (p<0.05) in exposed infants than controls on day 1. Brazelton scores for habituation, social-interactive, motor and autonomic clusters, and serotonin scores were significantly greater (p<0.05) in exposed infants.

Discussion: Transfer of SSRIs and SNRIs across the placenta was substantial. Neonates developed mild behavioral symptoms in the early perinatal period but these were self-limiting and similar for both SSRIs and the SNRI venlafaxine.

References

• 1 Agut-Quijano T, Martinez-Nadal S, Elizari-Saco MJ. et al . Neonatal withdrawal syndrome to selective serotonin reuptake inhibitors: case report and literature review.  Rev Neurol. 2006;  42 660-662
• 2 Bakker MK, Kolling P, Berg PB van den. et al . Increase in use of selective serotonin reuptake inhibitors in pregnancy during the last decade, a population-based cohort study from The Netherlands.  Br J Clin Pharmacol. 2008;  65 600-606
• 3 Begg EJ, Duffull SB, Saunders DA. et al . Paroxetine in human milk.  Br J Clin Pharmacol. 1999;  48 142-147
• 4 Bellantuono C, Migliarese G, Gentile S. Serotonin reuptake inhibitors in pregnancy and the risk of major malformations: a systematic review.  Hum Psychopharmacol. 2007;  22 121-128
• 5 Brazelton TB, Nugent JK. Neonatal behavioral assessment scale. 3rd edn. London, UK: Mac Keith Press 1995
• 6 Casper RC, Fleisher BE, Lee-Ancajas JC. et al . Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy.  J Pediatr. 2003;  142 402-408
• 7 Challis J, Sloboda D, Matthews S. et al . Fetal hypothalamic-pituitary adrenal (HPA) development and activation as a determinant of the timing of birth, and of postnatal disease.  Endocr Res. 2000;  26 489-504
• 8 Chambers CD, Hernandez-Diaz S, Marter LJ Van. et al . Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn.  New Engl J Med. 2006;  354 579-587
• 9 Chambers CD, Johnson KA, Dick LM. et al . Birth outcomes in pregnant women taking fluoxetine.  New Engl J Med. 1996;  335 1010-1015
• 10 Cox JL, Holden JM, Sagovsky R. Detection of postnatal depression. Development of the 10-item Edinburgh Postnatal Depression Scale.  Brit J Psychiatry. 1987;  150 782-786
• 11 Moor RA de, Mourad L, ter HJ. et al . Withdrawal symptoms in a neonate following exposure to venlafaxine during pregnancy.  Ned Tijdschr Geneeskd. 2003;  147 1370-1372
• 12 Dietz PM, Williams SB, Callaghan WM. et al . Clinically identified maternal depression before, during, and after pregnancies ending in live births.  Am J Psychiatry. 2007;  164 1515-1520
• 13 Ferreira E, Carceller AM, Agogue C. et al . Effects of selective serotonin reuptake inhibitors and venlafaxine during pregnancy in term and preterm neonates.  Pediatrics. 2007;  119 52-59
• 14 Finnegan LP, Connaughton  Jr  JF, Kron RE. et al . Neonatal abstinence syndrome: assessment and management.  Addictive Dis. 1975;  2 141-158
• 15 Heikkinen T, Ekblad U, Kero P. et al . Citalopram in pregnancy and lactation.  Clin Pharmacol Ther. 2002;  72 184-191
• 16 Heikkinen T, Ekblad U, Palo P. et al . Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation.  Clin Pharmacol Ther. 2003;  73 330-337
• 17 Hendrick V, Stowe ZN, Altshuler LL. et al . Placental passage of antidepressant medications.  Am J Psychiatry. 2003;  160 993-996
• 18 Hostetter A, Ritchie JC, Stowe ZN. Amniotic fluid and umbilical cord blood concentrations of antidepressants in three women.  Biol Psychiatry. 2000;  48 1032-1034
• 19 Ilett KF, Hackett LP, Dusci LJ. et al . Distribution and excretion of venlafaxine and O-desmethylvenlafaxine in human milk.  Br J Clin Pharmacol. 1998;  45 459-462
• 20 Isbister GK, Dawson A, Whyte IM. et al . Neonatal paroxetine withdrawal syndrome or actually serotonin syndrome?.  Arch Dis Child Fetal Neonatal Ed. 2001;  85 F147-F148
• 21 Koren G, Moretti M, Kapur B. Can venlafaxine in breast milk attenuate the norepinephrine and serotonin reuptake neonatal withdrawal syndrome.  J Obstet Gynaecol Can. 2006;  28 299-302
• 22 Kristensen JH, Hackett LP, Kohan R. et al . The amount of fluvoxamine in milk is unlikely to be a cause of adverse effects in breastfed infants.  J Hum Lact. 2002;  18 139-143
• 23 Kristensen JH, Ilett KF, Dusci LJ. et al . Distribution and excretion of sertraline and N-desmethylsertraline in human milk.  Br J Clin Pharmacol. 1998;  45 453-457
• 24 Kristensen JH, Ilett KF, Hackett LP. et al . Distribution and excretion of fluoxetine and norfluoxetine in human milk.  Br J Clin Pharmacol. 1999;  48 521-527
• 25 Laine K, Heikkinen T, Ekblad U. et al . Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations.  Arch Gen Psychiatry. 2003;  60 720-726
• 26 Lane R, Baldwin D. Selective serotonin reuptake inhibitor-induced serotonin syndrome: review.  J Clin Psychopharmacol. 1997;  17 208-221
• 27 Levinson-Castiel R, Merlob P, Linder N. et al . Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants.  Arch Pediatr Adolesc Med. 2006;  160 173-176
• 28 Moses-Kolko EL, Bogen D, Perel J. et al . Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications.  JAMA. 2005;  293 2372-2383
• 29 Oberlander TF, Grunau RE, Fitzgerald C. et al . Pain reactivity in 2-month-old infants after prenatal and postnatal serotonin reuptake inhibitor medication exposure.  Pediatrics. 2005;  115 411-425
• 30 Oberlander TF, Warburton W, Misri S. et al . Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data.  Arch Gen Psychiatry. 2006;  63 898-906
• 31 Pakalapati RK, Bolisetty S, Austin MP. et al . Neonatal seizures from in utero venlafaxine exposure.  J Paediatr Child Health. 2006;  42 737-738
• 32 Pearlstein T. Perinatal depression: treatment options and dilemmas.  J Psychiatry Neurosci. 2008;  33 302-318
• 33 Pirec V. Current dilemmas in treating depressed pregnant patients.  Psychopharm Rev. 2007;  42 91-98
• 34 Rampono J, Hackett LP, Kristensen JH. et al . Transfer of escitalopram and its metabolite demethylescitalopram into breastmilk.  Br J Clin Pharmacol. 2006;  62 316-322
• 35 Rampono J, Kristensen JH, Hackett LP. et al . Citalopram and demethylcitalopram in human milk; distribution, excretion and effects in breast fed infants.  Br J Clin Pharmacol. 2000;  50 263-268
• 36 Rampono J, Proud S, Hackett LP. et al . A pilot study of newer antidepressant concentrations in cord and maternal serum and possible effects in the neonate.  Int J Neuropsychopharmacol. 2004;  7 329-334
• 37 Rosack J. FDA Committee urges new warning on antidepressants for pregnancy.  Psychiatr News. 2004;  39 33
• 38 Salvia-Roiges MD, Garcia L, Gonce-Mellgren A. et al . Neonatal convulsions and subarachnoid hemorrhage after in utero exposure to paroxetine.  Rev Neurol. 2003;  36 724-726
• 39 Stiskal JA, Kulin N, Koren G. et al . Neonatal paroxetine withdrawal syndrome.  Arch Dis Child Fetal Neonatal Ed. 2001;  84 F134-F135
• 40 Suri R, Altshuler L, Hellemann G. et al . Effects of antenatal depression and antidepressant treatment on gestational age at birth and risk of preterm birth.  Am J Psychiatry. 2007;  164 1206-1213
• 41 Topliss D, Isaccs D, Lander C. et al . Maternal SSRI use and neonatal effects.  Aust Adverse Drug React Bull. 2003;  22 14
• 42 Zeskind PS, Stephens LE. Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior.  Pediatrics. 2004;  113 368-375

1 Previous presentation: An abstract of this manuscript was presented as a poster at the 12th Annual Congress of The Perinatal Society of Australia and New Zealand (PSANZ08), 20 to 23 April 2008, Gold Coast Convention and Exhibition Centre, Queensland, Australia.

Correspondence